Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Breast: MetastaticNCT ID: NCT01441947
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-208
The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in breast cancer tumor growth, its ability to spread, and its ability to form new blood vessels. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to prevent cancer growth. The single agent portion of this study is now closed to accrual. This research study is now examining the efficacy of cabozantinib in combination with fulvestrant for treatment of hormone-receptor-positive breast cancer that has spread to bone.
Conducting Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center
Overall PI: Steven Isakoff, MD, PhD,
Massachusetts General Hospital
Site-responsible Investigators: Sara Tolaney, MD,
Dana-Farber Cancer InstituteSteven Come, MD,
Beth Israel Deaconess Medical Center
Contacts: Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060